Background of Drug Discovery Targeting Lysosomal Degradation Pathways
Protein homeostasis refers to the highly complex and interconnected processes that cells use to maintain protein concentration, conformation and subcellular localisation. It contains a large number of pathways that control protein synthesis, folding, protein transport and disposal. In eukaryotic cells, damaged proteins or organelles can be cleared by proteasomes or lysosomes. Lysosomes are responsible for the degradation of long-lived proteins, insoluble protein aggregates and even whole organelles, macromolecular compounds and intracellular parasites through endocytosis, phagocytosis or the autophagic pathway. In recent years, proteolysis- targeting chimeric technology has emerged as one of the most promising approaches for the removal of specific disease-associated proteins by exploiting the cell's own destruction mechanisms. TPD via the lysosomal pathway represents a new tool for exploring cellular pathways and a promising therapeutic approach, greatly facilitating the design and development of drugs targeting disease-associated proteins.
Fig. 1. Summary of lysosome-dependent protein degradation strategies. (Allemailem K S, et al., 2021)
Solutions
Traditionally drug discovery has focused on the direct modulation of protein activity. The development and application of modulators of protein activity, particularly inhibitors, has been the mainstay of drug development. As a lysosomal innovator, CD BioSciences is committed to developing lysosomal-based targeted protein degradation (TPD) strategies to help you design small molecule drugs.
Lysosomes play an important role in protein degradation. Therefore, lysosome-induced protein-degrading drugs can directly modulate protein levels in vivo for the purpose of treating diseases, providing a new strategy for drug discovery. CD BioSciences, as a leading lysosome service provider with the most advanced lysosomal pathway and lysosome-based degradation technologies, is committed to providing global customers with comprehensive drug discovery solutions for targeting lysosomal degradation pathways.
Our lysosomal degradation technology holds promise for the treatment of diseases, particularly neurodegenerative diseases. Our goal is to help you facilitate the design, discovery and preclinical application of drugs associated with this technology. Depending on endocytosis and different forms of autophagy, Our dedicated team will ensure that you receive the most satisfactory solution for drug discovery targeting the lysosomal degradation pathway. Working closely with biotechnologists, our team of experts developed an overall small size, efficient, versatile and cell-type independent all-protein membrane protein degradation platform that selectively identifies and targets multiple cellular proteins to the autophagic membrane for lysosomal degradation.
Advantages of Our Solutions
- Our scientists are working on the development of several novel protein degradation technologies.
- While targeted protein degradation technologies can only degrade certain intracellular proteins, lysosomal-based targeted protein degradation technologies have the potential to remove protein aggregates and damage excess organelles, membrane proteins and extracellular proteins.
- The development of these technologies will provide powerful tools for biomedical research and holds great promise for future drug development.
- Significantly expanding the range of known molecules as substrates provides a new strategy for targeting many traditionally non-targeted proteins, such as backbone proteins and transcription factors, bacteria and viruses.
- Additional new strategies can be developed through lysosomal systems to selectively reduce the degradation of biological materials in vivo.
CD BioSciences has the most advanced lysosomal-based technologies for targeted protein degradation. Our experienced team of experts can help solve drug discovery problems for lysosomal-based targeted proteins degradation. Please feel free to contact us for a quote.
Reference
- Zhao L, Zhao J, Zhong K, et al. (2022) Targeted protein degradation: mechanisms, strategies and application[J]. Signal Transduction and Targeted Therapy. 7(1): 1-13.